The European healthcare technology and medical technology sectors have reached a definitive operational and financial inflection point. Following a period of post-pandemic recalibration, the transaction landscape has transitioned into an era of disciplined industrial maturity, widely characterised by market analysts as the "Great Rationalisation". The speculative business models of the early 2020s, which prioritised user acquisition and un-monetised top-line expansion, have b